Abstract
Background Considering the emergence of SARS-CoV-2 variants and low vaccine access and uptake, minimizing human interactions remains an effective strategy to mitigate the spread of SARS-CoV-2. The aim of this study was to create a novel multidimensional mobility index to capture the complexity of human interaction and evaluate its utility as an early indicator of surges in COVID-19 cases.
Methods We used publicly available anonymous cell phone data compiled by SafeGraph, from all counties in Illinois, Ohio, Michigan and Indiana between January 1st to December 8, 2020. Six metrics of mobility were extracted for each county. Changes in mobility were defined as a time-updated 7-day rolling average. We used an unsupervised machine learning method known as functional principal component analysis (fPCA) to construct the latent mobility index (MI) using the six metrics of mobility. Associations between our MI and COVID-19 cases were estimated using a quasi-Poisson hierarchical generalized additive model adjusted for population density and the COVID-19 community vulnerability index.
Results Individual mobility metrics varied significantly by counties and by calendar time. More than 50% of the variability in the data was explained by the first principal component by each state, indicating good dimension reduction. Following the expiration of stay-at-home orders, mobility increased across all counties and this was particularly evident on weekends. While an individual metric of mobility was not associated with surges of COVID-19, our MI was independently associated with COVID-19 cases in all four states given varying time-lags.
Conclusion Following the expiration of stay-at-home orders, a single metric of mobility was not sensitive enough to capture the complexity of human interactions. Monitoring mobility can be an important public health tool, however, it should be modelled as a multidimensional construct.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received no external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Projects based on publicly available data do not require McGill University IRB review. This research uses publicly available and anonymous data and is therefore exempt from institutional review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.